A Phase II Trial of the Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)
Phase of Trial: Phase II
Latest Information Update: 16 Jan 2019
At a glance
- Drugs Selumetinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- 12 Jan 2019 Planned initiation date changed from 11 Jan 2019 to 18 Jan 2019.
- 05 Jan 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 4 Jan 2019 to 11 Jan 2019 .
- 29 Dec 2018 Planned initiation date (estimated date for recruitment of the first subject) changed from 27 Dec 2018 to 4 Jan 2019 .